Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue $ 118,047 $ 0
Cost of goods sold 98,618 0
Gross profit 19,429 0
Research and development 1,265,707 4,926,714
General and administrative 7,271,461 7,855,220
Depreciation and amortization 42,000 21,000
Total operating expenses 8,578,753 12,802,949
Loss from operations (8,560,000) (12,803,000)
Interest income, net 1,000 40,000
Loss before income taxes (8,559,000) (12,763,000)
Income taxes (benefit) 0 0
Net loss (8,559,000) (12,763,000)
Non-controlling interest 239,421 1,428,000
Net loss attributable to BioSig Technologies, Inc. (8,319,000) (11,335,000)
Preferred stock dividend (2,000) (5,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (8,321,000) $ (11,340,000)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.26) $ (0.46)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 31,584,142 24,389,249
Product [Member]    
Revenue $ 115,367 $ 0
Service [Member]    
Revenue $ 2,680 $ 0